Press Releases

Press Releases

Date Title  
Apr 18, 2019
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
Results from final analysis of the composite primary endpoint were consistent with the futility analysis reported in April 2018 Results from post hoc analyses revealed a potential survival benefit with NEOD001 in the category of patients at the highest risk for early mortality ( Mayo Stage IV )
Mar 05, 2019
Prothena to Participate in Upcoming March Healthcare Conferences
DUBLIN, Ireland , March 05, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, today announced that members of its senior management team will present and participate in the following March investor conferences:  Barclays Global Healthcare
Feb 14, 2019
Prothena Reports Fourth Quarter and Full Year 2018 Financial Results, and Provides Financial Guidance and R&D Update
Net cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 million for the full year 2018; quarter-end cash and restricted cash position of $431.7 million provides funding to advance neuroscience pipeline Entered into global neuroscience research &
Feb 04, 2019
Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14
DUBLIN, Ireland , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14 th , after the close of the U.S. financial markets.
Nov 06, 2018
Prothena Reports Third Quarter 2018 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $33.7 million in the third quarter and $7.5 million in the first nine months of 2018; quarter-end cash and restricted cash position of $455.6 million provides funding to advance neuroscience pipeline DUBLIN, Ireland , Nov.
Oct 30, 2018
Prothena to Report Third Quarter 2018 Financial Results on November 6
DUBLIN, Ireland , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2018 on November 6, 2018 after the close of the U.S. financial markets.
Aug 07, 2018
Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
Net loss was $59.9 million in the second quarter and $108.6 million for the first six months ended June 30, 2018 Net cash from operating and investing activities was $58.0 million in the second quarter and  $26.3 million in the first six months of 2018; quarter-end cash and restricted cash position
Jul 31, 2018
Prothena to Report Second Quarter 2018 Financial Results on August 7

DUBLIN, Ireland , July 31, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the second quarter and first six months of 2018 on August 7, 2018 after the close of the U.S. financial markets.
Jun 25, 2018
Prothena Announces Appointment of Tran B. Nguyen as Chief Operating Officer

DUBLIN, Ireland , June 25, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience category, today announced that Tran B. Nguyen has been appointed to the newly created
Jun 19, 2018
Prothena Announces Phase 1b Clinical Trial Results of PRX002/RG7935 for Parkinson's Disease Published in JAMA Neurology

Data Previously Presented in 2017 at the 13th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) DUBLIN, Ireland , June 19, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel